ARK5蛋白在上皮性卵巢癌细胞卡铂耐药中的作用

Abstract
Figure/Table
References (0)
Related Citation (2)

Download: PDF (1495 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the mechanisms of carboplatin resistance in epithelial ovarian cancer (EOC) cells, and provide preliminary exploration on improving the effect of chemotherapy in ovarian cancer patients. Methods: Cell counting kit-8 was used to evaluate the effect of carboplatin on the proliferation of SKOV3 and A2780 cells, meanwhile the expression of epithelial-mesenchymal transition related proteins E-cadherin and vimentin were detected by Western blot. Flow cytometry assay was used to detect the expression of CD133. In addition, knockdown of ARK5 was to evaluate the role of ARK5 in the carboplatin-induced epithelial-mesenchymal transition. Results: The IC50 of carboplatin in SKOV3 and A2780 was 2.824 µg/mL and 1.760 µg/mL, respectively. Furthermore, we also found that carboplatin could significantly induce epithelial-mesenchymal transition in EOC cells. Carboplatin could increase the expression of ARK5, but not SNARK. Knockdown of ARK5 could attenuate the induction of epithelial-mesenchymal transition. Conclusion: ARK5 plays an important role in carboplatin resistance in EOC cells. Knockdown of ARK5 may reduce the carboplatin-induced epithelial-mesenchymal transition.

Key words： epithelial ovarian cancer cells epithelial-mesenchymal transition carboplatin ARK5

Received: 30 March 2017

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PAN Jiexue
	LIN Feng.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2017/V47/I11/805

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[2] ADAMS G, ZEKRI J, WONG H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?[J]. BJOG, 2010, 117(12): 1459-1467.
[3] KWON J S, MCGAHAN C, DEHAECK U, et al. The significance of combination chemotherapy in epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2014, 24(2): 226-232.
[4] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein[J]. J Biol Chem, 2003, 278(1): 48-53.
[5] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation[J]. Oncogene, 2003, 22(40): 6177-6182.
[6] CHANG X Z, YU J, LIU H Y, et al. ARK5 is associated with the invasive and metastatic potential of human breast cancer cells[J]. J Cancer Res Clin Oncol, 2012, 138(2): 247-254.
[7] CUI J, YU Y, LU G F, et al. Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma[J]. Tumour Biol, 2013, 34(3): 1913-1918.
[8] PHIPPEN N T, BATEMAN N W, WANG G, et al. NUAK1 (ARK5) is associated with poor prognosis in vvarian can-cer[J]. Front Oncol, 2016, 6, 213.
[9] ZHANG H Y, LI J H, LI G, et al. Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer[J]. Oncol Rep, 2015, 34(3): 1193-1202.
[10] COLEMAN R L, MONK B J, SOOD A K, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer[J]. Nat Rev Clin Oncol, 2013, 10(4): 211-224
[11] TEO M C. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer[J]. Curr Opin Obstet Gynecol, 2014, 26(1): 3-8.
[12] JELOVAC D, ARMSTRONG D K. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3): 183-203.
[13] FISCHER K R, DURRANS A, LEE S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance[J]. Nature, 2015, 527 (7579): 472-476.
[14] ZHENG X, CARSTENS J L, KIM J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer[J]. Nature, 2015, 527(7579): 525-530.
[15] 陈潇, 周浩, 周希, 等. 松弛素对TGF-β诱导的内皮细胞间质化的抑制作用[J]. 温州医科大学学报, 2014, 44(3): 161-165.
[16] DING Q, MIYAZAKI Y, TSUKASA K, et al. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis[J]. Mol Cancer, 2014, 13, 15.
[17] PAN J X, WANG F, YE L Y. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2016, 479(4): 610-614.
[18] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5[J]. Oncogene, 2004, 23(42): 7067-7075.